Accessibility Menu
Sumitomo Pharma logo

Sumitomo Pharma(OTC) DNPUF

Market Cap$3.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+7%
5 Year-57%
1 Year+16%
1 Month-11%
$8.41
+0.00%
+0.00Today
Sumitomo Pharma last closing stock price
MetricPriceDate
Last closeUSD 8.412026-07-21
Sumitomo Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 8.412026-07-14
1 month-10.68%USD 9.412026-06-17
3 month-29.96%USD 12.002026-04-21
Year to date-41.47%USD 14.362025-12-15
1 year+16.09%USD 7.242025-07-17
3 year+92.33%USD 4.372023-06-30
5 year-56.73%USD 19.422021-07-09
Since inception+7.07%USD 7.852004-04-20

Sumitomo Pharma Financials at a Glance

Market Cap

$3.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥476.32B

Net Income (TTM)

¥113.79B

EPS (TTM)

$1.87

P/E Ratio

4.49

Dividend

$0.00

Beta (Volatility)

0.07 (Low)

Price

$8.41

Volume

20

Open

$8.41

Previous Close

$8.41

Daily Range

$8.41 - $8.41

52-Week Range

$8.41 - $19.20

Estimated Earnings Date

Nov 4, 2026

DNPUF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sumitomo Pharma

Sumitomo Pharma Co., Ltd. is a global enterprise specializing in the manufacturing and distribution of a diverse portfolio of products, including pharmaceuticals, food ingredients, and veterinary medicines. Established in 1897 and headquartered in Osaka, Japan, the company operates in key international markets, notably Japan, North America, and China.

Products and Services
  • Pharmaceuticals for neurological, cardiovascular, and metabolic diseases
  • Food ingredients and additives for the food industry
  • Veterinary medicines for companion animals and livestock
Growth Outlook
  • Recent collaborations with leading research institutions enhance innovation potential
  • Expansion in North America and China supports revenue growth
  • Focus on developing treatments for chronic diseases aligns with market demand
Financial Highlights
  • Trailing twelve month revenue of 1.4 trillion JPY, indicating strong market presence
  • Net income of 88.9 billion JPY in Q2 2025, showcasing profitability
  • Operating income margin of 19.5% in Q2 2025 reflects operational efficiency
Sumitomo Pharma Co., Ltd. has established itself as a significant player in the healthcare sector, particularly in the pharmaceutical industry. The company's diverse product offerings cater to various medical conditions, which positions it well for future growth. Recent financial performance indicates a robust revenue stream and profitability, particularly in the second quarter of 2025. The strategic focus on innovation through collaborations and expansion into key markets further enhances its growth potential. Investors may find Sumitomo Pharma's commitment to addressing chronic diseases and its operational efficiency appealing as it navigates the evolving healthcare landscape.
AI Generated • Jul 27, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

3,123

CEO

Toru Kimura, PhD

Website

www.sumitomo-pharma.co.jp

Headquarters

Osaka, OS 541-0045, JP

DNPUF Financials

Key Financial Metrics (TTM)

Gross Margin

54.99%

Operating Margin

10.05%

Net Income Margin

23.73%

Return on Equity

35.89%

Return on Capital

9.88%

Return on Assets

13.33%

Earnings Yield

22.27%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

448.59M

Volume

20

Avg. Volume

98.159

Financials (TTM)

Gross Profit

¥262.04B

Operating Income

¥47.88B

EBITDA

¥128.83B

Operating Cash Flow

¥64.98B

Capital Expenditure

-¥3.81B

Free Cash Flow

¥61.17B

Cash & ST Invst.

¥76.09B

Total Debt

¥159.50B

Sumitomo Pharma Performance Analysis

Sumitomo Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 4,101,079,895-17.7%
20242024-03-31JPY 2,178,177,023-46.9%
20252025-03-31JPY 2,616,143,26320.1%
20262026-03-31JPY 3,008,081,01615.0%
Sumitomo Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-3011.9%
Q32025-12-31-0.1%
Q42026-03-31-12.0%
Q12026-06-3021.0%
Sumitomo Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY -1.38N/A
20242024-03-31JPY -5.49296.5%
20252025-03-31JPY 0.39N/A
20262026-03-31JPY 1.79357.5%
Sumitomo Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30694.0%
Q32025-12-31-90.1%
Q42026-03-31-109.3%
Q12026-06-301981.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥128.56B

+19.0%

Gross Profit

¥67.59B

+5.8%

Gross Margin

52.57%

N/A

Market Cap

$3.77BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.21M

N/A

Employees

3,123

N/A

Net Income

¥16.87B

+50.6%

EBITDA

¥22.15B

-15.6%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥76.09B

+272.0%

Total Debt

¥159.50B

-48.4%

Accounts Receivable

¥141.75B

+70.0%

Inventory

¥79.10B

-11.9%

Long Term Debt

¥118.79B

-54.1%

Short Term Debt

¥40.70B

-18.9%

Return on Assets

13.33%

N/A

Return on Invested Capital

8.18%

N/A

Free Cash Flow

-¥8.05B

-69511.8%

Operating Cash Flow

-¥7.39B

-554522.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNPHFSanten Pharmaceutical Co., Ltd.
$13.05+0.00%
CZMWYCarl Zeiss Meditec AG
$37.26+6.34%
CZMWFCarl Zeiss Meditec AG
$33.63-3.80%
HKMPYHikma Pharmaceuticals PLC
$45.36-1.86%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.08+0.08%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.59-0.01%
ONDSOndas
$9.15+0.03%
SPCXSpace Exploration Technologies
$138.87-0.02%

Questions About DNPUF

What is the current price of Sumitomo Pharma?

Sumitomo Pharma is trading at $8.41 per share.

What is the 52-week range for Sumitomo Pharma?

Over the past 52 weeks, Sumitomo Pharma has traded between $8.41 and $19.20.

How much debt does Sumitomo Pharma have?

As of the most recent reporting period, Sumitomo Pharma reported total debt of ¥988.51M.

How much cash does Sumitomo Pharma have on hand?

Sumitomo Pharma reported ¥471.56M in cash and cash equivalents in its most recent financial results.

What is Sumitomo Pharma’s dividend yield?

Sumitomo Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services